SGLT2 inhibitors represent one of the most remarkable therapeutic developments in heart failure care, transitioning from ...

We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. SGLT2 inhibitors reduce the risks for adverse kidney and ...

Real-world data reinforce SGLT2 inhibitors as first-line therapy for frail, older adults with heart failure with preserved ...

We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. SGLT2 inhibitors are the preferred for treating comorbid ...

Sean Virani, MD, lead author of the new guidelines and president of the CCS, explained that the guidelines use the term ...

In a recent study published in the European Heart Journal, researchers assessed the impact of sodium-dependent glucose co-transporter 2 (SGLT2) inhibitors on type 2 diabetes and heart failure (HF) ...

Compared with placebo, SGLT2 inhibitors reduced heart failure hospitalizations among patients with history of myocardial infarction. Sodium-glucose co-transporter 2 (SGLT2) inhibitors may ...

Comparative effectiveness study followed adults with type 2 diabetes who initiated SGLT-2 inhibitors from 2014 to 2020. Real-world outcomes largely point to comparable risks of hospitalization for ...

SGLT2 inhibitors reduce the risk for adverse kidney outcomes across most high-risk populations with CKD, heart failure, and/or type 2 diabetes. Sodium glucose cotransporter 2 inhibitors (SGLT2i) ...

Regardless of duration of type 2 diabetes, sodium-glucose cotransporter inhibitors prevented cardiovascular events, according to research presented at the European Society of Cardiology Congress 2024.

Two classes of diabetes drugs may also improve cardiovascular and kidney disease outcomes in people with or without diabetes. In a meta-analysis involving more than 70,000 patients with diabetes, ...